Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity

• URL: http://arxiv.org/abs/2201.06872v1
• Date: Tue, 18 Jan 2022 10:57:05 GMT
• Title: Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity
• Authors: Shrimon Mukherjee, Madhusudan Ghosh, Partha Basuchowdhuri
• Abstract summary: We propose a novel architecture that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. Our proposed model has been trained on Davis, KIBA (Kinase Inhibitor Bioactivity), DTC (Drug Target Commons), Metz, ToxCast and STITCH datasets. We use our novel architecture to predict a Combined Score (calculated using Davis and KIBA score) of 2,304 FDA-approved drugs against 5 viral proteins. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2. Subsequently, this list may be used for the creation of new useful drugs.

Related papers

• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Knowledge-Driven New Drug Recommendation [88.35607943144261]
  We develop a drug-dependent multi-phenotype few-shot learner to bridge the gap between existing and new drugs. EDGE eliminates the false-negative supervision signal using an external drug-disease knowledge base. Results show that EDGE achieves 7.3% improvement on the ROC-AUC score over the best baseline.
  arXiv  Detail & Related papers  (2022-10-11T16:07:52Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• Evening the Score: Targeting SARS-CoV-2 Protease Inhibition in Graph Generative Models for Therapeutic Candidates [11.853524110656991]
  We look at the therapeutic design of novel drug candidates targeting SARS-CoV-2 viral proteins. We use an autoencoder that generates molecules with similar structures to a dataset of drugs with anti-SARS activity. During generation, we explore optimization toward several design targets to balance druglikeness, synthetic accessability, and anti-SARS activity.
  arXiv  Detail & Related papers  (2021-05-07T18:39:25Z)
• SafeDrug: Dual Molecular Graph Encoders for Safe Drug Recommendations [59.590084937600764]
  We propose a DDI-controllable drug recommendation model named SafeDrug to leverage drugs' molecule structures and model DDIs explicitly. On a benchmark dataset, our SafeDrug is relatively shown to reduce DDI by 19.43% and improves 2.88% on Jaccard similarity between recommended and actually prescribed drug combinations over previous approaches.
  arXiv  Detail & Related papers  (2021-05-05T00:20:48Z)
• Genetic Constrained Graph Variational Autoencoder for COVID-19 Drug Discovery [0.0]
  We propose a new model called Genetic Constrained Graph Variational Autoencoder (GCGVAE) to solve this problem. We trained our model based on the data of various viruses' protein structure, including that of the SARS, HIV, Hep3, and MERS, and used it to generate possible drugs for SARS-CoV-2. Our generated molecules have great effectiveness in inhibiting SARS-CoV-2.
  arXiv  Detail & Related papers  (2021-04-23T16:10:15Z)
• Dr-COVID: Graph Neural Networks for SARS-CoV-2 Drug Repurposing [14.112444998191698]
  We propose a dedicated graph neural network (GNN) based drug repurposing model, called Dr-COVID. Dr-COVID is evaluated in terms of its prediction performance and its ability to rank the known treatment drugs for diseases as high as possible.
  arXiv  Detail & Related papers  (2020-12-03T18:34:10Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)
• Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19 [6.7410870290301]
  The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. Here, we deploy algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics.
  arXiv  Detail & Related papers  (2020-04-15T17:40:29Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.